1. Vietnam Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Binh Dinh Pharmaceutical & Medical Equipment JSC

Binh Dinh Pharmaceutical & Medical Equipment JSC

HHOSE:DBD
46,750.00
VND
+650.00
(+1.41%)
4.91TMarket Cap
Dec 02Next Earn
Binh Dinh Pharmaceutical & Medical Equipment JSC
HOSE:DBD
(Ho Chi Minh Stock Exchange)

Recent

price

46,750.00

P/E

ratio

- -

div

yld

0.01%

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
VND
14,963.84
13,476.08
13,426.12
16,658.81
16,619.45
17,655.83
18,465.84
19,870.53
- -
Revenue per Share
1,741
1,519.08
1,686.18
2,021.54
2,603.35
2,875.94
2,941.43
3,109.83
- -
Basic EPS, GAAP
681.22
-1,609.19
1,636.12
672.68
878.47
1,589.06
1,239.77
2,200.91
-458.84
Free Cash Flow per Basic Share
839.17
838.76
839
807.58
- -
1,600.13
0.11
1,977.37
6.44
Dividend per Share
9,512.76
9,959.79
10,567.23
12,191.21
14,485.03
15,315.61
17,756
18,372.24
18,383.19
Book Value per Share
8,968.43
9,357.25
9,907.39
11,545.47
13,842.4
14,693.51
17,148.61
17,501.88
17,211.37
Tangible Book Value per Share
94
94
94
94
94
94
94
94
94
Basic Weighted Avg Shares
1,401,024
1,261,729
1,256,952
1,558,504
1,554,821
1,651,770
1,727,548
1,865,380
- -
Sales/Revenue/Turnover
13.32
12.74
14.46
13.93
17.58
17.98
17.57
17.49
- -
Operating Margin (%)
36,517
27,945
31,809
38,689
41,665
45,970
48,112
51,021
- -
Depreciation Expense
163,005
142,227
157,860
189,124
243,555
269,055
275,182
291,940
- -
Net Income, GAAP
18.91
18.27
18.29
18.64
18.42
15.94
15.36
15.64
- -
Effective Tax Rate (%)
11.63
11.27
12.56
12.13
15.66
16.29
15.93
15.65
- -
Profit Margin (%)
523,917
448,496
487,973
661,231
842,332
842,697
1,016,126
892,366
886,915
Working Capital
- -
65,453
62,726
76,000
60,000
44,000
28,000
132,000
226,070
LT Debt
890,654
932,508
988,626
1,140,549
1,355,137
1,432,842
1,661,141
1,735,979
1,737,014
Total Equity
- -
12.92
13.58
16.04
18.06
18.13
16.91
15.85
- -
Return on Invested Capital (%)
- -
13.94
14.54
16.47
18.66
18.68
17.21
16.24
- -
Return on Capital (%)
- -
15.6
16.43
17.76
19.52
19.3
17.79
17.19
- -
Return on Common Equity (%)

Capital Structure

VND

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
43,215
51,033
31,006
LT Borrowings
132,000
218,000
226,070
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
94
94
Market Capitalization
4,611,076
4,885,095
4,913,442

Working Capital

VND

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,480,040
1,536,021
1,599,206
Cash, Cash Equivalents & STI
611,985
570,676
524,745
Accounts Receivable, Net
495,347
514,009
494,251
Inventories
366,110
421,442
530,805
Total Current Liabilities
587,674
513,118
712,291
Payables & Accruals
- -
- -
- -
ST Debt
43,215
51,033
31,006
Deferred Revenue
- -
- -
- -

Growth Rates

VND

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.07%
4.51%
Free Cash Flow
- -
21.75%
78.14%
Net Income, GAAP
- -
13.48%
6.09%
Sales/Revenue/Turnover
- -
8.51%
7.98%
Total Cash Common Dividend
- -
- -
1,868,668.81%

Quarterly Revenue

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
383,779
433,050
432,818
477,901
1,727,548
2025
441,045
474,537
- -
509,952
1,865,380
2026
448,087
471,666
- -
- -
- -

Quarterly Earnings Per Share

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
717.74
773.79
801.9
647.99
2,941.43
2025
865.91
965.61
- -
629.63
3,109.83
2026
849.81
943.73
- -
- -
- -

Quarterly Dividends Per Share

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
1.11
1,977.37
2026
3.83
1.5
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company (Bidiphar) is a Vietnam-based pharmaceutical and healthcare company engaged in the research, development, manufacturing, and commercialization of pharmaceutical preparations, specialized therapeutics, and medical equipment. The company's core product portfolio encompasses specialized oncology and antineoplastic pharmaceuticals; sterile small-volume and large-volume injectables; hemodialysis concentrates and peritoneal dialysis solutions; systemic antibiotics, cephalosporins, and other anti-infective formulations; cardiovascular, metabolic, and central nervous system therapeutics; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; vitamins, mineral dietary supplements, and therapeutic nutrition products; standardized herbal medicines and bioactive phytotherapeutic compounds; and specialized medical machinery and healthcare apparatus, including medical solid waste incinerators, automated herbal extraction and brewing systems, and water distillation equipment. Bidiphar supplies national and provincial healthcare institutions through the hospital-based ethical drug channel (ETC) as well as commercial retail pharmacy networks across Vietnam through the over-the-counter (OTC) channel, while exporting finished formulations to international markets across Southeast and Central Asia, including Cambodia, Laos, Myanmar, and Mongolia. In recent operational and strategic developments, Bidiphar has advanced a multi-facility expansion program focused on European Union Good Manufacturing Practice (EU-GMP) compliance to qualify for high-tier institutional public hospital tenders. The company inaugurated a dedicated oncology pharmaceutical manufacturing facility in the Nhon Hoi Economic Zone and commenced construction of an 840 billion VND EU-GMP standard sterile small-volume injectable manufacturing plant. Additionally, the company initiated the development of an 870 billion VND non-betalactam oral solid dosage (OSD) manufacturing facility and approved private placement equity offerings to secure international strategic pharmaceutical partners for advanced technology transfer and export market expansion. Founded in 1979, converted to a joint-stock enterprise in 2014, and listed on the Ho Chi Minh Stock Exchange under the ticker symbol DBD, Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company is headquartered in Quy Nhon, Binh Dinh Province, Vietnam.